EvaluatePharma: NOVARTIS Top 1º sales league 2018...$51.3 billion.

The EP report also claims that "in the race to become the top pharmaceutical company, in terms of total prescription drug sales, Novartis will emerge as a clear leader in 2018", with turnover forecast to reach $51.3 billion by that year. That is $3 billion ahead of its closest competitors, Pfizer and Sanofi (in a previous analysis, EP said the French drugmaker would knock the US behemoth off the top slot in 2012, a position Pfizer held for nine years, and retain that position until at least 2016). (Más)

• 1º.-Novartis, $51.3 billion, up from $46.7 billion in 2011

• 2º.-Pfizer, $48.2 billion, down from $53.5 billion

• 3º.-Sanofi, $48.2 billion, up from $39.3 billion

• 4º.-GlaxoSmithKline, $44.9 billion, up from $34.9 billion

• 5º.-Roche, $43.9 billion, up from $37 billion

• 6º.-Merck & Co., $40.6 billion, down from $41.9 billion

Ver anterior:

Sanofi lidera la "pole position"...2012